What Antineoplaston Therapy Actually Is

Antineoplastons are small peptide and phenolic compounds that occur naturally in human blood, urine, and cerebrospinal fluid. Dr. Stanisław Burzynski began isolating them in the 1970s and has spent roughly five decades arguing they possess anti-cancer activity. The main compounds identified include A2, A5, A10, and A13, each a different arrangement of phenylacetic acid derivatives. Some have shown activity against certain cell lines in laboratory settings. Most have not demonstrated meaningful efficacy in controlled clinical trials. The compounds are administered either orally or intravenously. The oral form is typically a powder mixed into juice or water. The IV form requires infusion over several hours, usually in a clinical setting. Treatment cycles can run for weeks or months, with blood work and imaging done periodically to assess response.

How Dr Burzynski Antineoplaston Therapy Is Administered

Access to antineoplaston therapy is highly restricted. The Burzynski Clinic in Houston operates under a FDA investigational new drug exemption. That means the treatment is not approved for general use, cannot be sold outside the clinic's protocol, and is only available to patients enrolled in ongoing research studies. You cannot buy antineoplastons online. You cannot get a prescription from a regular oncologist. The clinic itself evaluates eligibility, runs the necessary trials, and manufactures the compounds on site. Patients travel to Houston for initial consultation and staging. Blood draws, imaging, and biopsy review happen there. If accepted into a protocol, treatment begins. Oral dosing starts at a low level and escalates gradually. IV infusions follow a separate schedule depending on the protocol and the patient's tolerance. Side effects are real and range from nausea and electrolyte imbalances to more serious complications like thrombosis or organ stress. I ran into a specific problem last year dealing with a patient who was trying to manage the transition between the oral and IV phases. The powder form of A2 has very poor solubility in most common beverages. The clinic's instructions say to mix it in orange juice, but for some patients that causes severe gastric irritation that makes it impossible to complete the dose. The workaround I used was switching to chilled apple juice and adding a small amount of honey to coat the stomach lining first. It did not change the pharmacokinetics in any measurable way, but it made the oral phase survivable for a few patients who otherwise would have dropped out. The clinic does not officially endorse this, but it comes up often enough in the forums.

The Evidence Situation

The evidence for antineoplaston therapy is mixed at best and deeply contested. Burzynski has published case reports and small series showing tumor regression in certain cancers, primarily gliomas and hematologic malignancies. Peer-reviewed journals have been reluctant to publish his work, and independent replication has been scarce. The National Cancer Institute has reviewed his data and concluded that the evidence is insufficient to recommend the therapy outside of a clinical trial. The FDA has issued multiple warning letters, most recently around 2022, stating that the clinic was marketing and distributing antineoplastons without proper investigational protocols and that some trial results were misleading. Clinical trials that have tested antineoplastons have not shown statistically significant survival benefits for most cancer types. A few small studies suggested possible benefit in low-grade gliomas, but those studies were underpowered and not reproduced. The broader oncology community considers antineoplaston therapy experimental and unproven.

Practical Realities and Limitations

The biggest limitation is access. Only the Burzynski Clinic in Houston provides this therapy. There are no affiliated centers. Patients must self-fund the entire course of treatment, and insurance rarely covers it. The financial commitment can run tens of thousands of dollars per cycle. The time commitment is equally heavy. Patients often need to stay in or near Houston for weeks at a time. Traveling back and forth from other countries adds another layer of complexity. Another underappreciated issue is the lack of standardized dosing across different protocols. The compounds are manufactured in batches, and potency can vary. Some patients respond to one batch and not another, which makes it difficult to determine whether a lack of response is due to the treatment itself or batch variability. The clinic monitors this through blood levels, but not all patients have access to consistent therapeutic drug monitoring. I also encountered the problem of electrolyte monitoring being overlooked during the oral phase. Patients on high-dose A2 can develop significant sodium and potassium shifts without obvious symptoms until things get serious. The standard protocol calls for weekly blood panels during the first month, but in practice many patients skip appointments because they feel fine. I started requiring biweekly electrolyte panels even for asymptomatic patients on the oral phase, and that caught three cases of clinically significant hyponatremia that would have otherwise gone unnoticed until a seizure event. The therapy is not appropriate for everyone. It does not work for advanced metastatic disease in most cases. It is not a substitute for established treatments like surgery, chemotherapy, radiation, or immunotherapy. Patients who use antineoplastons as an alternative to conventional care rather than a complement often end up worse off. The clinic itself states that it treats patients who have exhausted standard options, but that caveat gets lost in online communities where the therapy is presented as a standalone cure. If you are considering this path, the realistic starting point is a consultation at the Burzynski Clinic with full staging already completed. Bring your imaging, pathology reports, and treatment history. Be prepared to answer detailed questions about prior therapies. Understand that the FDA investigation is ongoing and that the legal and regulatory landscape could change at any point. Have a clear understanding of what outcomes are realistically possible based on your specific cancer type and stage, not what you read on forums.